Suppr超能文献

烟酰胺腺嘌呤二核苷酸(NAD+)补充剂在体内和体外均减轻了慢性睡眠限制(CSR)诱导的小胶质细胞促炎反应。

NAD+ supplement relieved chronic sleep restriction (CSR)-induced microglial proinflammation in vivo and in vitro.

作者信息

Chen Qiqiang, Xiao Jinrong, Lin Zhenya, Xu Xin, Chen Jinlan

机构信息

Department of Anesthesiology, The 900 Hospital of the Joint Logistic Support Force of the People's Liberation Army of China, Fuzhou 350025, China.

Department of Cardiothoracic Surgery, The 900 Hospital of the Joint Logistic Support Force of the People's Liberation Army of China, Fuzhou 350025, China.

出版信息

J Neuroimmunol. 2024 Dec 15;397:578469. doi: 10.1016/j.jneuroim.2024.578469. Epub 2024 Oct 24.

Abstract

Sleep insufficiency is a significant health problem worldwide and can induce multiple neurodevelopmental disorders in the central nervous system (CNS). Sleep deprivation (SD), especially chronic SD, leads to cognition and memory loss and worsens neurodegenerative disease liability. Microglia are the main inflammation-dominant glia and play a crucial role in SD-induced neurological impairments. Nicotinamide adenine dinucleotide (NAD+) is a redox reaction coenzyme that exerts anti-inflammatory and mitochondria-protective effects in microglia. Whether NAD+ mitigated SD-induced neurological disorders by regulating microglial functions is still unknown. In the current study, we designed an in vivo and in vitro model to evaluate the neuroprotective effect of NAD+ on chronic sleep restriction (CSR) and further investigate the underlying mechanisms. Behavioral tests and immunofluorescence staining were applied to investigate the cognition impairments and microglial activation. Biochemical experiments were tested to analyze the oxidative status and possible mechanism. In vitro data were used to verify the in vivo data. Our results displayed that NAD+ supplement mitigated CSR-induced cognitive decline and microglial activation response by suppressing the expression of pro-inflammatory cytokines in vivo. NAD+ administration also decreased oxidative stress and mitochondrial impairments in microglia. In vitro results showed that NAD+ treatment inhibited ROS production and prompted M1 conversion to M2 phenotype. cGAS-STING/NF-κB pathways were significantly activated but down-regulated by NAD+ administration. H151, a STING antagonist, was applied to validate that NAD+ treatment alleviates neuroinflammation partially by regulating cGAS-STING pathways in microglia. Our findings suggest that NAD+ supplement is a promising therapy for sleep disorders-induced neurological problems, and cGAS-STING pathway may act as a critical regulator in microglial proinflammation.

摘要

睡眠不足是一个全球性的重大健康问题,可诱发中枢神经系统(CNS)的多种神经发育障碍。睡眠剥夺(SD),尤其是慢性SD,会导致认知和记忆丧失,并加重神经退行性疾病易感性。小胶质细胞是主要的炎症主导型胶质细胞,在SD诱导的神经损伤中起关键作用。烟酰胺腺嘌呤二核苷酸(NAD+)是一种氧化还原反应辅酶,在小胶质细胞中发挥抗炎和线粒体保护作用。NAD+是否通过调节小胶质细胞功能减轻SD诱导的神经障碍仍不清楚。在本研究中,我们设计了体内和体外模型,以评估NAD+对慢性睡眠限制(CSR)的神经保护作用,并进一步研究其潜在机制。应用行为测试和免疫荧光染色来研究认知障碍和小胶质细胞激活。进行生化实验以分析氧化状态和可能的机制。体外数据用于验证体内数据。我们的结果显示,补充NAD+通过抑制体内促炎细胞因子的表达减轻了CSR诱导的认知下降和小胶质细胞激活反应。给予NAD+还降低了小胶质细胞中的氧化应激和线粒体损伤。体外结果表明,NAD+处理抑制了活性氧的产生,并促使M1型向M2型表型转化。cGAS-STING/NF-κB通路被显著激活,但通过给予NAD+而下调。应用STING拮抗剂H151来验证NAD+处理通过调节小胶质细胞中的cGAS-STING通路部分减轻了神经炎症。我们的研究结果表明,补充NAD+是治疗睡眠障碍引起的神经问题的一种有前景的疗法,并且cGAS-STING通路可能是小胶质细胞促炎的关键调节因子。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验